Video content above is prompted by the following: Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on ...

Therapeutic antibody eculizumab caught in action Date: June 3 ... protein from the innate immune system called C5 which is cleaved by enzymes when pathogens invade our body as a defense mechanism.

The global biopharmaceutical company Alexion, headquartered in the U.S., has developed a therapeutic antibody called eculizumab that prevents the cleavage of C5 and thereby treats the two diseases.

The recent approval of eculizumab as a first-in-class complement inhibitor for ... M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of ...

Eculizumab was approved for MG in 2017 and has become a standard of care in later-line treatment. Ravulizumab, ... A biologic drug with a totally different mechanism of action, ...

Owing to the mechanism of action of eculizumab, our patient was vaccinated against meningococcal infection before the initiation of eculizumab treatment. 5.

Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due ...

Eculizumab was administered, and ... Current knowledge indicates that different mechanisms lead to the development of the lesions associated with dense-deposit disease. 1 Our observations show ...